Group 1: Biomedical Engineering Innovations - Recent advancements in biomedical engineering are reshaping the future of health, with innovations such as 3D printed organs and smart prosthetics [3][12] - In June 2025, a research team in China discovered a "molecular switch" for mammalian organ regeneration, enabling injured adult mice to regrow ear cartilage and nerve tissue [1] - The world's first living heart organoid, over 1 centimeter in diameter, was successfully cultivated in Shanghai, derived from human stem cells, offering new hope for organ transplantation [1][4] Group 2: Organoid Technology and Applications - Organoids are miniaturized organ models created from stem cells that can simulate real organ structures and functions, useful for disease modeling and drug screening [4][11] - The process of 3D printing active organoids requires billions of cells, with advancements in bioprinting technology allowing for the creation of complex structures [5][9] - Current applications include printing skin, cartilage, and small organoids for clinical use, while more complex organ printing is still in research stages [11][12] Group 3: Drug Testing and Personalized Medicine - High-throughput organoid printing technology allows for the simulation of cancer patient tumors, enabling efficient drug testing without the need for blind trials on patients [14] - This method allows for simultaneous testing of multiple drugs and dosages, streamlining the process of finding effective treatment options [14] Group 4: Cross-Disciplinary Collaborations - Recent developments in vision prosthetics demonstrate the potential of interdisciplinary collaboration, with a team creating a wide-spectrum visual prosthetic that enables blind animals to perceive infrared light [17][18] - The project involved multiple national key laboratories, showcasing a new paradigm of innovation in biomedical engineering through cross-laboratory cooperation [24] Group 5: Strategic Industry Development - Shanghai has initiated an innovation ecosystem for organoids since 2021, focusing on drug screening and personalized medicine [26] - Hubei aims to grow its biopharmaceutical industry to 250 billion by 2027, emphasizing organoid technology as a key direction [26] - Shenzhen has included cutting-edge fields like cell therapy and gene therapy in its support measures for the pharmaceutical and medical device sectors [26]